SecBot SecBot
SECBOTREPLAY Home › Report › FBRX

FBRX · Forte Biosciences reported a net loss per share of $(4.71) for FY 2025,…

Forte Biosciences, Inc. · 8-K filed Apr 1, 2026 at 08:00 ET

At the news

BEARISHIMPACT 7/10

8-K filed Apr 1, 2026 at 08:00 ET

Forte Biosciences reported a net loss per share of $(4.71) for FY 2025, missing consensus estimates, with R&D expenses nearly tripling due to clinical trial advancement. This follows a recent $150M follow-on offering, raising concerns about capital efficiency.

  • Net loss per share was $(4.71) for FY 2025, missing consensus of $-1.16
  • R&D expenses increased to $58.2M from $21.2M in 2024 due to clinical trials
  • Cash and cash equivalents decreased to $77.0M from $93.4M in Q3 2025
  • Recent $150M follow-on offering completed just 12 days prior to earnings

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access